Marshall Edwards, Inc. to Present at BIO Investor Forum 2007
October 03 2007 - 9:40AM
PR Newswire (US)
NEW CANAAN, Conn., Oct. 3 /PRNewswire-FirstCall/ -- Marshall
Edwards, Inc. (NASDAQ:MSHL) will present at the BIO Investor Forum
2007 at the San Francisco Palace Hotel on Thursday, October 11,
2007 at 12:00 pm. About Marshall Edwards, Inc. Marshall Edwards,
Inc. (NASDAQ:MSHL) is a specialist oncology company focused on the
clinical development of novel anti-cancer therapeutics. These
derive from a flavonoid technology platform which has generated a
number of novel compounds characterized by broad ranging efficacy
against a range of cancer targets with few side effects. The unique
combination of efficacy and safety has been explained by their
ability to target an enzyme present on the surface of cancer cells,
thereby inhibiting the production of pro-survival proteins within
the cell. Marshall Edwards, Inc. has licensed rights from Novogen
Limited (NASDAQ:NVGN) to bring three oncology drugs -- phenoxodiol,
NV-196 and NV-143 -- to market globally. The Company's lead
investigational drug, phenoxodiol, is in a Phase III multinational
multi-centered clinical trial for patients with recurrent ovarian
cancer. More information on the trial can be found at
http://www.ovaturetrial.com/. Marshall Edwards, Inc. is majority
owned by Novogen, an Australian biotechnology company that is
specializing in the development of therapeutics based on a
flavonoid technology platform. Novogen, based in Sydney, Australia,
is developing a range of therapeutics across the fields of
oncology, cardiovascular disease and inflammatory diseases. More
information on phenoxodiol and on the Novogen group of companies
can be found at http://www.marshalledwardsinc.com/ and
http://www.novogen.com/ . Under U.S. law, a new drug cannot be
marketed until it has been investigated in clinical trials and
approved by the FDA as being safe and effective for the intended
use. Statements included in this press release that are not
historical in nature are "forward-looking statements" within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. You should be aware that our actual
results could differ materially from those contained in the
forward-looking statements, which are based on management's current
expectations and are subject to a number of risks and
uncertainties, including, but not limited to, our failure to
successfully commercialize our product candidates; costs and delays
in the development and/or FDA approval, or the failure to obtain
such approval, of our product candidates; uncertainties in clinical
trial results; our inability to maintain or enter into, and the
risks resulting from our dependence upon, collaboration or
contractual arrangements necessary for the development,
manufacture, commercialization, marketing, sales and distribution
of any products; competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary rights to third
party patents and intellectual property to operate our business;
our inability to operate our business without infringing the
patents and proprietary rights of others; general economic
conditions; the failure of any products to gain market acceptance;
our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry
practice; and one-time events. We do not intend to update any of
these factors or to publicly announce the results of any revisions
to these forward-looking statements. DATASOURCE: Marshall Edwards,
Inc. CONTACT: David Sheon, +1-202-518-6321, for Marshall Edwards,
Inc. Web site: http://www.marshalledwardsinc.com/
http://www.novogen.com/ http://www.ovaturetrial.com/
Copyright
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024